Chemokine Receptor 2 Is a Theranostic Biomarker for Abdominal Aortic Aneurysms

作者：Santiago Elizondo-Benedetto, Sergio Sastriques-Dunlop, Lisa Detering, Batool Arif, Gyu Seong Heo, Deborah H. Sultan, Hannah P. Luehmann, Xiaohui Zhang, Xuefeng Gao, Andrea L. Bredemeyer, Mohamed Zaghloul, Kitty Harrison, Dakkota Thies, Laura McDonald, Christophe Combadière, Chieh‐Yu Lin, Yeona Kang, Jie Zheng, Joseph E. Ippolito, Richard A. Laforest, Kory J. Lavine, Robert J. Gropler, Sean J. English, M.A. Zayed, Yongjian Liu · 发表于：JACC Basic to Translational Science · 年份：2025 · DOI：10.1016/j.jacbts.2025.02.010 · 被引用次数：10 · 研究领域：Aortic aneurysm repair treatments、Aortic Disease and Treatment Approaches、Infectious Aortic and Vascular Conditions

Abdominal aortic aneurysm (AAA) is a degenerative vascular disease with a high mortality upon rupture. There is no diagnosis to predict the rupture nor effective medical therapies to prevent rupture. Here we demonstrate that the C-C chemokine receptor type 2 (CCR2) is a theranostic biomarker for AAA. In rat AAA models, we determined the potential of a CCR2-targeted positron emission tomography radiotracer [64Cu]Cu-DOTA-ECL1i predicting AAA rupture. Using a CCR2 inhibitor, we observed the effective prevention of rupture in AAA rat models. In humans, CCR2 positron emission tomography showed intense radiotracer uptake along the AAA wall in patients while little signal was observed in healthy volunteers.